GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
Source: Sharecast
It was understood the company is planning to axe around 50 roles at its main R&D hub in Stevenage, Hertfordshire.
A spokesperson for the drugs giant said in a statement: "GSK R&D investment has risen by almost 90% over recent years (to £6.4bn in 2024) and we expect it to increase further as we focus on delivering our pipeline of new medicines with multi-blockbuster potential before 2031.
"As we increase investment, we’re focused on allocating resources to these priorities and making sure we have the right people in the right teams. Alongside this, we’re investing in technology to maximise our scientific capabilities and drive productivity, and in our key R&D sites over the next five years to accelerate drug discovery and research."
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
